Lantern Pharma Inc.(LTRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LTRN Lantern Pharma Inc.

Closed 01-09 16:00:00 EST

3.49

+0.10

+2.95%

盘后3.49

+0.000.00%

17:12 EST

High3.60	Low3.35	Vol52.95K
Open3.37	D1 Closing3.39	Amplitude7.37%
Mkt Cap39.03M	Tradable Cap29.97M	Total Shares11.18M
T/O183.08K	T/O Rate0.62%	Tradable Shares8.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LTRN","market":"US","secType":"STK","nameCN":"Lantern Pharma Inc.","latestPrice":3.49,"timestamp":1767992400000,"preClose":3.39,"halted":0,"volume":52950,"hourTrading":{"tag":"盘后","latestPrice":3.49,"preClose":3.49,"latestTime":"17:12 EST","volume":28,"amount":99.16,"timestamp":1767996777524},"delay":0,"floatShares":8587400,"shares":11184423,"eps":-1.752393,"marketStatus":"Closed","change":0.1,"latestTime":"01-09 16:00:00 EST","open":3.37,"high":3.6,"low":3.35,"amount":183081.01077,"amplitude":0.073746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.752393,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":5,"adr":0,"listingDate":1591848000000,"exchange":"NASDAQ","adjPreClose":3.39,"postHourTrading":{"tag":"盘后","latestPrice":3.49,"preClose":3.49,"latestTime":"17:12 EST","volume":28,"amount":99.16,"timestamp":1767996777524},"volumeRatio":0.932445,"impliedVol":0.7865,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/LTRN","defaultTab":"news","newsList":[{"id":"2588678041","title":"Lantern Pharma Inc: Clinical Trial Met All Primary Endpoints for Safety, Tolerability, and Established a Clear Recommended Phase 2 Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2588678041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588678041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:36","pubTimestamp":1764768977,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90S3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2588041343","title":"Lantern Pharma : Reports Additional Positive Lp-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041343?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:36","pubTimestamp":1764768977,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90S3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2588041321","title":"Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041321","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041321?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:35","pubTimestamp":1764768914,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLxT6VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2583523901","title":"Lantern Pharma’s Q3 2025: Clinical and AI Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523901","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523901?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:16","pubTimestamp":1763093776,"startTime":"0","endTime":"0","summary":"Lantern Pharma, Inc. ( ($LTRN) ) has released its Q3 earnings. Here is a breakdown of the information Lantern Pharma, Inc. presented to its investo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lantern-pharmas-q3-2025-clinical-and-ai-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lantern-pharmas-q3-2025-clinical-and-ai-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU2065732104.USD","PRGS","BK4139","LTRN"],"gpt_icon":0},{"id":"2583594520","title":"Lantern Pharma posts Q3 net loss of $4.2 million as LP-184 trial meets primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594520","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583594520?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:26","pubTimestamp":1763047594,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. reported a net loss of $4.2 million for the third quarter of 2025, compared to a net loss of $4.5 million in the same period of 2024. Net loss per common share, basic and diluted, was $0.39, down from $0.42 in the prior year period. Total operating expenses were $4.3 million, a decrease from $5.2 million in 2024. Cash, cash equivalents, and marketable securities totaled $12.4 million as of September 30, 2025, compared to $24.0 million at the end of 2024. Total assets were $13.6 million, with total liabilities of $4.0 million and stockholders' equity of $9.6 million. Key business developments for the period included completion of the Phase 1a clinical trial for LP-184, achieving all primary endpoints with a 48% clinical benefit rate in evaluable cancer patients at or above the therapeutic dose threshold. Lantern Pharma also advanced enrollment in the first-in-human clinical trial for LP-284 in non-Hodgkin lymphoma and other cancers, and reported initial clinical data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9qfxgn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2583593632","title":"Lantern Pharma Inc Qtrly Net Loss $0.39 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593632","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593632?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA4N5STD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2583931765","title":"Press Release: Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583931765","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583931765?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040600,"startTime":"0","endTime":"0","summary":"Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch. --  LP-184 Phase 1a clinical trial results demonstrate all primary. endpoints achieved with 48% clinical benefit rate in evaluable cancer. patients at or above therapeutic dose threshold; marked tumor reductions. observed in patients with DNA damage repair mutations including CHK2, ATM,--  FDA Type C meeting completed, providing regulatory guidance and pathway. clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in. --  LP-300 preliminary Phase 2 data presented from the HARMONIC trial. at the 66th Annual Meeting of the Japan Lung Cancer Society with further. clinical and patient data planned for a webinar in December.--  LP-284 clinical data showcased at 25th Annual Lymphoma, Leukemia &. Myeloma  Congress, generating interest from the biopharma and. clinical communities and initiating discussions for combination therapy. --  KOL-hosted","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4551","BK4139","BK4516","STRK","03160","BK4543","BK4600","BK4595","AI","BK4023","BK4099","BK4232","KOL","LTRN","BK4528","R","BK4604","BK4022","BK4588","BK4596","BK4585","BK4587","BK4555"],"gpt_icon":1},{"id":"2583569589","title":"Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569589","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:03","pubTimestamp":1763031801,"startTime":"0","endTime":"0","summary":"Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48828383/lantern-pharma-q3-eps-0-39-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN"],"gpt_icon":0},{"id":"2582730382","title":"Lantern Pharma management to meet virtually with Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2582730382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582730382?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:25","pubTimestamp":1762961142,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on November 20 hosted by Lake Street. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-management-to-meet-virtually-with-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-management-to-meet-virtually-with-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2582810885","title":"Lantern Pharma CEO Showcases AI-Driven Oncology Advances on Bloomberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810885","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810885?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:08","pubTimestamp":1762740510,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7FysBz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2581865318","title":"Lantern Pharma Partners with New to The Street for National Media Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2581865318","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581865318?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524057,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. , an artificial intelligence-driven cancer drug development company, has announced a comprehensive media partnership with New to The Street, a leading business television and multi-platform media brand. The collaboration will span a full year and include national TV interviews, commercial campaigns, earned media placements, and billboard exposure in New York City's Financial District and Times Square. The partnership aims to increase awareness of Lantern Pharma's AI-powered platform and clinical-stage drug pipeline, with coverage set to air on Bloomberg Television and Fox Business Network, as well as across digital, social, and outdoor media channels.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL8D3pVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2581931770","title":"Lantern Pharma Inc. to Release Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581931770","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581931770?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434207,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire  on November 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL2Hqbd4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2580496802","title":"Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2580496802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580496802?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:15","pubTimestamp":1762193743,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc.  has released a presentation detailing its current drug development pipeline and the role of its proprietary AI platform, RADR, in accelerating oncology drug discovery. The presentation highlights Lantern's portfolio of drug candidates, including LP-300, which is in Phase 2 trials for non-small cell lung cancer in never smokers, and LP-184 and LP-284, which target various cancer indications and are at different stages of clinical development. The company reports that its AI-driven approach has enabled significant reductions in early-stage development timelines and costs, as well as high accuracy in patient stratification for clinical trials. The presentation also outlines Lantern's ongoing clinical trials, collaborations, and opportunities for partnering and licensing with other biopharma and technology companies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL4wvQZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2580913312","title":"Lantern Pharma Inc  expected to post a loss of 47 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580913312","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580913312?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:03","pubTimestamp":1762167793,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc  expected to post a loss of47cents a share - Earnings Preview Lantern Pharma Inc LTRN.OQ LTRN.O is expected to  show no change in quarterly revenue when it reports  results on Novem","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF0ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2579121436","title":"Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2579121436","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579121436?lang=en_us&edition=fundamental","pubTime":"2025-10-30 23:43","pubTimestamp":1761838995,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. has published a new presentation highlighting its advancements in AI-driven oncology drug development. The company showcased its proprietary RADR platform, which is designed to accelerate cancer drug discovery and development while reducing associated costs. According to the presentation, RADR can predict and stratify patient responses for clinical trials with 88% accuracy, helping to compress early-stage drug development timelines by 70% and reduce costs by 80%. The presentation details Lantern's pipeline, which includes 10 disclosed drug programs and five clinical stage lead candidates, such as LP-300 for non-small cell lung cancer in never smokers  and LP-284 for recurrent non-Hodgkin's lymphomas . The company has launched 10 new programs in two years and has active ongoing Phase 1 and Phase 2 clinical trials. RADR is also being utilized to identify biomarkers and increase the probability of clinical trial success. You can access the full presentation through the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL5X2b6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"gpt_icon":0},{"id":"2578542629","title":"Lantern Pharma Reports Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2578542629","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578542629?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:49","pubTimestamp":1761655754,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. has announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma  Congress, held October 14-17, 2025, in New York City. The data included a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma  who had experienced disease progression after four prior treatments, including CAR-T cell therapy and bispecific antibody therapy. Lantern Pharma reported that follow-up assessment with response durability data is expected by the end of 2025. The company is also conducting ongoing partnership discussions for combination therapy trial development and expanding clinical site activation to accelerate enrollment. LP-284 has multiple FDA Orphan Drug Designations and is being evaluated for additional applications in autoimmune and inflammatory conditions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL2pwYmD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2578495447","title":"Lantern Pharma Presents Lp-284 Clinical Data at 25TH LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted Dlbcl Patient & Therapeutic Potential in Advanced B-Cell Cancers.","url":"https://stock-news.laohu8.com/highlight/detail?id=2578495447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578495447?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:49","pubTimestamp":1761655740,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA75GSKN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2578772686","title":"Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578772686","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578772686?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:17","pubTimestamp":1761607038,"startTime":"0","endTime":"0","summary":"Lantern Pharma, Inc. (($LTRN)) announced an update on their ongoing clinical study. Lantern Pharma, Inc. is conducting a clinical study titled ‘Pha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lantern-pharmas-promising-phase-ii-lung-cancer-study-key-insights-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lantern-pharmas-promising-phase-ii-lung-cancer-study-key-insights-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","LTRN","BK4139","ISBC"],"gpt_icon":0},{"id":"2569461907","title":"Lantern Pharma Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569461907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569461907?lang=en_us&edition=fundamental","pubTime":"2025-09-24 04:46","pubTimestamp":1758660399,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. held its 2025 Annual Meeting of Stockholders on September 19, 2025. During the meeting, stockholders voted on several proposals. All six nominated directors, Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein, were elected to the board of directors. The proposal to approve a one-time repricing of certain stock options under the Lantern Pharma Inc. 2018 Equity Incentive Plan was approved. Additionally, the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL4vCQcY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"gpt_icon":0},{"id":"2568938499","title":"Lantern Pharma (LTRN) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2568938499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568938499?lang=en_us&edition=fundamental","pubTime":"2025-09-17 20:55","pubTimestamp":1758113743,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Lantern Pharma today and set a price target of $25.00. The company’s shares closed yeste...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lantern-pharma-ltrn-gets-a-buy-from-lake-street-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lantern-pharma-ltrn-gets-a-buy-from-lake-street-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LTRN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lanternpharma.com","stockEarnings":[{"period":"1week","weight":0.1188},{"period":"1month","weight":-0.1263},{"period":"3month","weight":-0.2189},{"period":"6month","weight":-0.0788},{"period":"1year","weight":-0.1352},{"period":"ytd","weight":0.1188}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.044553},{"month":2,"riseRate":0.4,"avgChangeRate":-0.00833},{"month":3,"riseRate":0.6,"avgChangeRate":0.157412},{"month":4,"riseRate":0.2,"avgChangeRate":-0.150119},{"month":5,"riseRate":0.6,"avgChangeRate":0.019748},{"month":6,"riseRate":0.4,"avgChangeRate":-0.03205},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.020452},{"month":8,"riseRate":0.5,"avgChangeRate":0.052764},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.071519},{"month":10,"riseRate":0,"avgChangeRate":-0.151349},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098056},{"month":12,"riseRate":0.5,"avgChangeRate":0.047826}],"exchange":"NASDAQ","name":"Lantern Pharma Inc.","nameEN":"Lantern Pharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lantern Pharma Inc.(LTRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lantern Pharma Inc.(LTRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lantern Pharma Inc.,LTRN,Lantern Pharma Inc.股票,Lantern Pharma Inc.股票老虎,Lantern Pharma Inc.股票老虎国际,Lantern Pharma Inc.行情,Lantern Pharma Inc.股票行情,Lantern Pharma Inc.股价,Lantern Pharma Inc.股市,Lantern Pharma Inc.股票价格,Lantern Pharma Inc.股票交易,Lantern Pharma Inc.股票购买,Lantern Pharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lantern Pharma Inc.(LTRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lantern Pharma Inc.(LTRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}